Tanja Fehm News Today : Breaking News, Live Updates & Top Stories | Vimarsana

A safety analysis following a randomized phase 3 trial confirms that vomiting and nausea are common in patients who take the drug trastuzumab deruxtecan to treat HER2-low metastatic breast cancer.

United statesSan franciscoDaiichi sankyoRoche genentechTanja fehmPorto alegreGustavo werutskyEuropean society for medical oncology breast cancerUniversity of californiaUniversity hospitalHope rugoEuropean societyMedical oncology breast cancerNew england journalMoinhos de vento hospitalScorpion therapeutics